Ampio Pharmaceuticals (DB:APH) - Cours de l'action, nouvelles et analyse

APH Aperçu des actions

A biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. Plus de détails

APH analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	4/6
Dividendes	0/6

Analyse des risques

Les revenus ont diminué de 28.9% par an au cours des 5 dernières années

N'a pas de capitalisation boursière significative ( €2M )

Réalise moins d'un million de dollars de revenus ( $0 )

Les actions sont très illiquides

+ 2 plus de risques

Ampio Pharmaceuticals, Inc. Concurrents

Biofrontera

XTRA:B8FK

€16.3m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€57.6m

Redx Pharma

DB:0RX

€65.0m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Ampio Pharmaceuticals
Historique des cours de bourse
Prix actuel de l'action	US$3.62
Plus haut sur 52 semaines	US$7.40
Plus bas sur 52 semaines	US$2.48
Bêta	2.35
1Variation sur 1 mois	0%
Variation sur 3 mois	7.10%
Variation sur 1 an	n/a
3Variation sur 3 ans	-81.53%
Variation sur 5 ans	-49.58%
Évolution depuis l'introduction en bourse	-94.09%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	APH	DE Pharmaceuticals	DE Marché
7D	0%	1.6%	1.1%
1Y	n/a	-19.0%	7.2%

Rendement vs Industrie: Données insuffisantes pour déterminer la performance de APH par rapport au secteur German Pharmaceuticals.

Rendement vs marché: Données insuffisantes pour déterminer la performance de APH par rapport au marché German.

Volatilité des prix

Is APH's price volatile compared to industry and market?
APH volatility
APH Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: APH n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de APH au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
n/a	5	Mike Martino	ampiopharma.com

Ampio Pharmaceuticals, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Ampio Pharmaceuticals se comparent-ils à sa capitalisation boursière ?
APH statistiques fondamentales
Capitalisation boursière	€1.47m
Bénéfices(TTM)	-€8.17m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-0.2x

Ratio P/E

Le site APH est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
APH compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$0
Marge brute	US$0
Autres dépenses	US$8.80m
Les revenus	-US$8.80m

Derniers bénéfices déclarés

Sep 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-10.57
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de APH?

Voir les performances historiques et les comparaisons

APH Aperçu des actions

Analyse des risques

Ampio Pharmaceuticals, Inc. Concurrents

XTRA:B8FK

€16.3m

DUSE:SBX

€27.9m

XTRA:HIGH

€57.6m

DB:0RX

€65.0m

Historique des prix et performances

Nouvelles et mises à jour récentes

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: €0.98

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - €0.69